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1,3-Butadiene (BD) is a known rodent and human carcinogen
that is metabolized mainly by P450 2E1 to three epoxides,
1,2-epoxy-3-butene (EB), 1,2:3,4-diepoxybutane (DEB), and 1,2-
epoxy-3,4-butanediol. The individual epoxides vary up to 200-fold
in their mutagenic potency, with DEB being the most mutagenic
metabolite. It is important to understand the internal formation
of the individual epoxides to assign the relative risk for each
metabolite and to understand the molecular mechanisms re-
sponsible for extensive species differences in carcinogenicity. This
study presents a comprehensive exposure-response for the
formation of the DEB-specific N,N-(2,3-dihydroxy-1,4-butadiyl)-
valine (pyr-Val) in mice and rats. Using nano-ultra high pressure
liquid chromatography-tandem-mass spectrometry allowed anal-
ysis of pyr-Val in mice and rats exposed to BD as low as 0.1 and
0.5 ppm BD, respectively, and demonstrated significant differences
in the amounts and exposure-response of pyr-Val formation. Mice
formed 10- to 60-fold more pyr-Val compared to rats at similar
exposures. The formation of pyr-Val increased with exposures, and
the formation was most efficient with regard to formation per parts
per million BD at low exposures. While formation at higher
exposures appeared linear in mice, in rats formation saturated at
exposures ‡ 200 ppm for 10 days. In rats, amounts of pyr-Val were
lower after 20 days than after 10 days of exposure, suggesting that
the lifespan of rat erythrocytes may be shortened following
exposure to BD. This research supports the hypothesis that the
lower susceptibility of rats to BD-induced carcinogenesis results
from greatly reduced formation of DEB following exposure to BD.
Key Words: butadiene diepoxide; molecular dosimetry;
N-terminal valine adducts.
1,3-Butadiene (BD) is an important industrial chemical and
indirect alkylating agent that people are exposed to during the
production of synthetic rubber and resins (Himmelstein et al.,
1997) and as a byproduct of incomplete combustion in cigarette
smoke, auto exhaust, and fossil fuels (Agency for Toxic
Substances and Disease Registry [ATSDR], 1993). BD has
been recently rated the cigarette constituent with the highest
cancer risk index (Fowles and Dybing, 2003). Epidemiologic
studies have shown an increased incidence of leukemia in
workers exposed to BD in synthetic rubber production and an
increase in lymphohematopoietic cancers in BD production
workers that was not exposure related (International Agency for
Research on Cancer [IARC], 2008). Most agencies (ATSDR,
National Toxicology Program [NTP], and U.S. Environmental
Protection Agency [U.S. EPA]) have classified BD as a human
carcinogen based on evidence from epidemiologic and animal
studies (ATSDR, 1993; IARC, 2008; NTP, 2005; U.S. EPA,
2002). BD is a multispecies multisite carcinogen in rodents,
with mice being a much more sensitive species than rats (IARC,
2008). The complexity of BD carcinogenesis largely has been
attributed to species-dependent differences in BD metabolism.
BD is metabolized to several epoxide metabolites that are
known to bind to DNA and proteins. For BD risk assessment,
the mode of action is assumed to be that of a DNA-reactive
compound and the corresponding key events have been listed
by Preston (2007) based on the U.S. EPA guidelines for risk
assessment. Formation of promutagenic DNA adducts that
subsequently lead to mutations represent the causal link
between exposure and tumor development (Preston, 2007).
BD-derived epoxides differ in their mutagenic potency up to
200-fold with DEB being the most mutagenic metabolite
(Meng et al., 2007; Walker et al., 2009). To improve the
scientific basis of BD risk assessment, it is important to have
detailed knowledge of the internal formation of each
potentially mutagenic metabolite and its dependence on
species, gender, and exposure concentrations.
While not causally linked with carcinogenesis, protein
adducts have been widely used as surrogate biomarkers for
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internal exposure and DNA adduct formation. Protein adducts
and especially N-terminal valine adducts of hemoglobin are
well suited to study carcinogen metabolism across species for
the following reasons (Boysen et al., 2007a; Törnqvist et al.,
2002): First, they are good surrogate biomarkers for the internal
formation of reactive metabolites. Second, in molecular
epidemiology studies, blood specimens are more easily
obtained than tissues. Third, they are not removed by
enzymatic repair systems like DNA adducts. Fourth, they
accumulate over the lifetime of the erythrocytes, which is about
45, 63, and 120 days for mice, rats, and humans, respectively.
Fifth, since they represent cumulative exposure prior to
sampling, the time of sample collection is less critical. Lastly,
the N-terminal valine is freely accessible to alkylating agents in
all species, allowing interspecies comparisons relative to
metabolism and cancer risk. Therefore, N-terminal valine
adducts are valuable biomarkers to study the internal formation
of the reactive metabolites of BD-derived epoxides.
BD is metabolized primarily by P450 2E1 to 1,2-
epoxybutene (EB), 1,2:3,4-diepoxybutane (DEB), and 3,4-
epoxy-1,2-butanediol (EB-diol) (Himmelstein et al., 1997) that
produce various hemoglobin adducts shown in Figure 1. EB
produces N-(2-hydroxy-3-buten-1-yl)-valine (HB-Val), and
DEB forms N,N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val)
and 2,3,4-trihydroxybutyl-valine (THB-Val). The later adduct
is also formed from EB-diol and is present in unexposed
animals and humans from endogenous sources (Koc et al.,
1999). THB-Val and HB-Val adducts can be readily measured
using the modified Edman degradation followed by liquid-
liquid extraction and analysis by gas chromatography-mass
spectrometry (GC-MS or GC-MS/MS) (Booth et al., 2004;
Powley et al., 2005; Törnqvist et al., 1986). Unfortunately, the
presence of a tertiary amine makes pyr-Val unsuitable for
analysis by Edman degradation. Therefore, a proteomics
approach was established for the analysis of pyr-Val in rodents
(Boysen et al., 2004; Kautiainen et al., 2000). This method
utilized trypsin hydrolysis and immunoaffinity (IA) purification
prior to quantitation of the N-terminal pyr-Val (1–7) peptide by
liquid chromatography-tandem-mass spectrometry (LC-MS/
MS). We report herein a comprehensive exposure-response
of pyr-Val formation in male and female mice and rats that had
been exposed to various concentrations of BD by inhalation.
Exposures ranged from 0.1 to 625 ppm for 10 days and from
1.0 to 62.5 ppm for 20 days.
MATERIALS AND METHODS
Materials. Trypsin (biotin-agarose, from bovine pancreas) was purchased
from Sigma-Aldrich (St Louis, MO). All reagents and solvents were ACS grade
or higher. Centricon-3 filters were obtained from Amicon Inc. (Beverly, MA),
and Microspin filter tubes (regenerated cellulose, 0.2 lm) were from Alltech
Associates Inc. (Deerfield, IL). Polyclonal antibodies against pyr-Val (1–11)
were raised by Anaspec (San Jose, CA) using a standard peptide synthesized as
described previously (Jayaraj et al., 2003).
Animals and exposures. The exposures were performed at the Lovelace
Respiratory Research Institute (Albuquerque, NM) according to protocols
approved by the Institutional Animal Care and Use Committee. B6C3F1 mice
(male and female) and F344 rats (male and female) were exposed by inhalation
to 0.1, 0.5, 1, 1.5, 6.25, 62.5, 200, or 625 ppm BD for 10 days (2 weeks, 5 day/
week, and 6 h/day). In addition, mice and rats were exposed to 1, 6.25, or
62.5 ppm BD for 20 days (4 weeks, 5 day/week, and 6 h/day). The animals
were exposed to BD using multitiered whole-body exposure chambers
(H-2000; Lab Products, Aberdeen, MD). The total volume of the H-2000
chamber is 1.7 m3. The flow rate through each chamber was maintained at 15 ±
2 air changes per hour. All chamber supply air was high efficiency particulate
air-filtered before being introduced into the chamber supply system. Exposures
were conducted using BD gas delivered to each chamber from compressed gas
cylinders. Flow from each cylinder was controlled via a rotameter. Rodents in
one chamber received filtered air only as a control group, and rodents in other
chambers received BD. Each exposure was operated for 6 h þ T90 (time to
reach 90% of the target concentration) per exposure day. T90 values for each
exposure level were determined prior to the start of exposures.
Vapor concentrations in exposure chambers were monitored by two
independent methods. A MIRAN infrared spectrometer was used periodically
to monitor chamber vapor concentration in real time via infrared absorbance.
The MIRAN infrared spectrometer is a single-beam variable filter infrared
spectrometer, and the gas cell parameters, wavelength, and path length were
adjusted for optimal operation. In the backup quantification of BD in the
atmospheres, grab samples were collected three times daily during each
exposure day, and the samples were analyzed by GC. BD atmospheres were
compared to five-point calibration curves that spanned the exposure range
required to measure with accuracy the lower and upper ends of the BD
exposure concentrations used in rodent inhalation studies. At no time did the
BD exposure atmosphere concentration exceed the upper calibration concen-
tration. Analysis of BD exposure atmospheres by GC and a flame ionization
detector revealed no impurities, attesting to both the stability of the exposure
atmosphere and the lack of detectable impurities in the reference BD (certified
as > 99% pure).
At the end of the last exposure, animals were killed by exsanguination under
CO2 anesthesia and blood samples were collected by cardiac puncture within
2 h of the last exposure. Red blood cells were isolated, washed twice with 0.9%
saline, diluted 23 in distilled water, and stored at 80C before extraction of
globin.
Quantitation of pyr-Val. Amounts of pyr-Val were measured based on
a procedure described by Boysen et al. (2004) using peptide standards that had
been quantified accurately as described by Bordeerat et al. (2009). In brief,
FIG. 1. BD metabolism and formation of N-terminal valine adducts. The
numbers in EB-diol are based on the metabolism and are not in accordance with
IUPAC nomenclature.
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globin isolation was performed according to Mowrer et al. (1986). Globin
samples of 10–50 mg (depending on the species and the exposures) were
dissolved in 1.5 ml of 0.1M NH4HCO3 and 2 pmol of internal standard
[2H3]N,N-(2,3-dihydroxy-1,4-butadiyl)-valine ([
2H3]pyr-Val) (1–11) peptide
was added. Samples were digested for 24 h at 37C with 50–100 ll of trypsin-
biotin-agarose suspension (washed in advance twice with 0.1M NH4HCO3).
After Centricon-3 filtration, samples were dried and redissolved in 600-ll PBS
buffer, loaded on IA columns, and left capped for 1 h. After extensive washing
with distilled water (5 3 7 ml) and elution in 3 ml of 5% formic acid, followed
by sample drying, filtration on Microspin filters, and final drying, samples
were stored at 20C until analysis by nano-ultra high pressure liquid
chromatography-tandem-mass spectrometry (nano-UPLC-MS/MS).
Liquid chromatography and mass spectrometry. The quantitative anal-
ysis of the pyr-Val and [2H3]pyr-Val by nano-LC-MS/MS was performed with
an nano-UPLC (Waters, Milford, MA) coupled to a TSQ-Quantum Ultra triple
quad mass analyzer (ThermoFinnigan, San Jose, CA). The system utilized
a 2.0 3 20–mm Symmetry C18, 5-lm column (Waters) as a ‘‘trap column’’ for
samples loading at 15 ll/min 15mM ammonium formate-0.7% formic acid for
1 min. After sample loading, the flow rate was reduced to 1.2 ll/min and the
column exit flow was directed to an ‘‘analytical column’’ consisting of
a 100 lm 3 100–mm BEH C18 UPLC column (Waters). pyr-Val and [2H3]-
pyr-Val were eluted with a linear gradient of 5% acetonitrile/15mM ammonium
formate-0.7% formic acid for 2 min then to 70% acetonitrile/15mM ammonium
formate-0.7% formic acid for 10 min at a flow rate of 1.2 ll/min. The retention
times for the analyte and internal standard were determined with authentic
standards, and pyr-Val and [2H3]pyr-Val were detected in selected reaction
monitoring mode, monitoring the transitions of the double-charged ions m/z
417.25–158.25 and m/z 418.75–158.75, respectively. The electrospray
conditions were spray voltage of 1800 V and capillary temperature of 240C.
Collision energy was 28 V.
Statistical analysis. Statistical analyses were performed using Microsoft
Excel spreadsheet analysis tools. The amounts of pyr-Val adduct formation are
reported as average and SD (mean ± SD) for each animal group. In addition, the
interanimal variability was determined by calculating the coefficient of
variation (CV). It was calculated as the mean of amount pyr-Val divided by
SD and reported as a percentage. Comparisons of gender differences in adduct
levels were made by a Student’s t-test (two-sample unequal variances). The
analyses were performed separately for mice and rats. A significant difference
was defined by p < 0.05.
RESULTS
The peptide method was used for analysis of pyr-Val in
mice and rats exposed to low concentrations of BD. Using
nano-UPLC-MS/MS instead of capillary-LC-MS/MS in-
creased sensitivity (The limit of detection was 1 fmol and
the limit of quantitation was 4 fmol on column) and allowed
detection of pyr-Val in mice and rats exposed to BD as low
as 0.1 and 0.5 ppm, respectively. The amounts of pyr-Val in
rats exposed to 0.1 ppm were below the limit of detection.
Overall, in mice, the CV within each group was < 25%
(except for the 0.1 ppm exposures), while in rats, larger CVs
were observed. However, positive controls consisting of
control globin spiked with authentic 1–11 peptide standards
from both species and had CV < 10%, demonstrating the
accuracy and interday and intraday reproducibility of the
assay (data not shown). The larger CV in rats suggests larger
interanimal variability in rats than in mice. The amounts of
pyr-Val formed in mice and rats are presented in Table 1 and
representative ion chromatograms for pyr-Val in mice and
rats exposed to 1 ppm BD for 10 days are shown in Figure 2.
Exposure-Response of pyr-Val Formation in Mice
The exposure-responses of pyr-Val formation in male and
female B6C3F1 mice are plotted in Figures 3A and 3B. The
formation of pyr-Val increased with exposure, and the slopes
of formation were steepest at exposures  1.5 ppm (Fig. 3A,
insert) independent of exposure duration (10 or 20 days).
Formation of pyr-Val in mice also increased with prolonged
exposure and was 3.4 ± 0.7–fold higher after 20 days compared
to 10 days of exposure (Table 1). There were no significant
gender differences in mice at the exposure concentrations and
durations studied.
Exposure-Response of pyr-Val Formation in Rats
The exposure-responses of pyr-Val formation in male and
female F344 rats are plotted in Figures 3C and 3D. In female
rats exposed for 10 days, progressive decreases in the slope for
formation of pyr-Val were found at exposures between 1.5 and
62.5 ppm BD (b < 1) with a plateau in formation found at
exposures of 200 ppm BD and above (Fig. 3C). Similar
changes in slope may also occur after 10 days of exposures in
male rats, but there are currently insufficient data points to
determine the slope at low BD exposures. After 20 days of
exposure, progressive decreases in slope were observed
between exposures to 1, 6.25, and 62.5 ppm BD (b < 1)
(Fig. 3D). In contrast to the findings in mice, there were no
significant differences between 10- and 20-day exposures to 
6.25 ppm BD in the formation of pyr-Val in rats (Table 1).
Surprisingly, in female rats, the amounts of pyr-Val were
significantly lower after 20 days compared to 10 days of
exposure (Table 1). At lower exposures, amounts of pyr-Val
were higher after 20 days compared to 10 days of exposure, but
the number of data points was insufficient for establishing
a biphasic dose-response over time.
Formation of pyr-Val in Mice Compared to Rats
After 10 days of exposure, female mice formed 10 ± 2.5-fold
more DEB, measured as pyr-Val formation, than rats at similar
exposures. After 20 days of exposure, mice had increasingly
more pyr-Val than rats. With increasing exposure concen-
trations for 10 days, the decreases in slope for pyr-Val were
most apparent at exposures above 1.5 and 6.25 ppm BD in
mice and rats, respectively. The exposure-response curve
reached a plateau in rats at exposures of 200 ppm or greater,
while it increased more linearly in mice (Fig. 3, Table 1).
DISCUSSION
Determination of the molecular dose of DEB is critical for
understanding the mechanisms of BD carcinogenesis and
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mutagenesis because in vitro DEB is ~100 and 200-fold more
mutagenic than most of the stereochemical forms of EB and
EB-diol, respectively (Himmelstein et al., 1997). The analyses
of HB-Val and THB-Val have greatly enhanced our knowledge
of BD metabolism across species. The first data on the
formation of DEB in rats and mice after inhalation exposures
were reported by Boysen et al. (2004). In that communication,
the DEB-specific pyr-Val adduct was determined in mice
and rats exposed to three different concentrations of BD.
Comparisons of pyr-Val to previous measurements of HB-Val
and THB-Val adducts suggest that DEB may indeed be the
most important BD-derived metabolite for inducing mutations
(Boysen et al., 2007a).
The current investigation greatly extends our knowledge by
providing data on the formation of pyr-Val from a comprehen-
sive series of exposures to BD in mice and rats. B6C3F1 mice
and F344 rats were exposed by inhalation to concentrations of
BD ranging from 0.1 to 625 ppm. For perspective, ambient BD
concentrations in BD monomer and polymer plant work places
have ranged from 0.3 to 3 ppm (IARC, 2008). Cigarette smoke
and side stream tobacco smoke contains as much as 169 and
42 ppm BD, respectively, as determined by real-time analysis
of exhaled breath condensate (Gordon et al., 2002). Therefore,
the low exposures applied herein are representative of
occupational- and smoking-related human exposures and
should be more informative than previous data from higher
exposures of BD. The recently established peptide assay
allowed analysis of pyr-Val after exposures known to induce
tumors in rodents and down to those encountered in
occupational settings. As expected, the amount of pyr-Val
increases with exposure in both species. However, significant
species differences in the magnitude and patterns of exposure-
response for pyr-Val formation were observed.
From the limited data available previously, it was suggested
that formation of pyr-Val was highest at low exposures and that
extrapolation of the high exposure data would not go through
zero. To investigate the formation of DEB at low exposures in
detail, several exposures were carried out with BD concen-
trations below 3 ppm, which was the lowest concentration
previously analyzed for pyr-Val. The presented exposure-
response curves for pyr-Val clearly establish a change in the
slope at exposures below 1.5 and 6.25 ppm in mice and rats,
respectively (see inserts in Figs. 3A and 3C). In mice,
exposures below 1.5 ppm BD (10 days) produced about
21 pmol pyr-Val/g globin/ppm BD, while at exposures greater
than 1.5 ppm, this rate decreased as much as 10-fold at higher
exposures, reaching 2.5 pmol pyr-Val/g globin/ppm BD at
625 ppm (Table 1).
Previously, it had been noted that the amounts of pyr-Val
were similar in F344 rats exposed to 62.5 ppm BD for 20 days
TABLE 1
Amounts of pyr-Val Adducts (picomoles per gram of globin) in Mice and Rats after Inhalation Exposures to BD
Duration Gender BD exposure (ppm)
B6C3F1 mice F344 rats
n Mean ± SD %CV Adducts/ppm BD n Mean ± SD %CV Adducts/ppm BD
10 days Females 0 11 ND 4 ND
0.1 5 2.1 ± 1.3 62 21 5 ND
0.5 5 10.5 ± 2.5 24 21 6 0.7 ± 0.1 10 1.4
1 5 20.2 ± 2.0 10 20 5 2.0 ± 0.2 11 2.0
1.5 3 38.2 ± 2.2 6 26 6 3.4 ± 0.2 6 2.3
6.25 5 75.8 ± 10 13 12 5 9.1 ± 0.9 9 1.7
62.5 5 419 ± 63 15 6.7 8 47 ± 8.3 18 0.7
200 4 739 ± 99 13 3.7 10 120 ± 36 30 0.6
625 7 1532 ± 362 24 2.5 4 119 ± 14 12 0.2
Males 0 6 ND 6 ND
0.1 5 3.1 ± 1.1 35 31 5 ND
0.5 5 15.4 ± 2.0 13 31 5 0.6 ± 0.3 47 1.2
1.5 5 49.8 ± 8.6 17 33 5 1.5 ± 1.0 62 1.0
200 5 859 ± 126 15 4.3 10 119 ± 25 21 0.6
625 5 1980 ± 195 10 3.2 8 125 ± 33 27 0.2
20 days Females 0 3 ND 5 ND
1 3 53.7 ± 9.5 18 54 6 4.1 ± 1.5 37 4.1
6.25 7 290 ± 58 20 46 6 9.9 ± 1.7 17 1.5
62.5 6 1571 ± 456 29 25 6 29.4 ± 12 42 0.5
Males 0 ND 5 ND
1 6 65.6 ± 21 32 66 6 3.3 ± 1.7 52 3.3
6.25 6 379 ± 34 9 61 6 7.1 ± 1.6 23 1.1
62.5 6 1385 ± 227 16 22 6 21.5 ± 8.3 35 0.3
Note. ND, not detected.
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compared to Crl:CD rats exposed to 1000 ppm for 90 days
(Boysen et al., 2007a; Swenberg et al., 2008), suggesting
saturation for pyr-Val formation in rats. This earlier evidence,
however, was confounded by the fact that different strains and
duration of exposures were combined for interpretation. The
data reported herein show that the amount of pyr-Val in F344
rats reaches a plateau at exposures of 200 ppm BD and above
for 10 days (Fig. 3C). The saturation curve for pyr-Val in rats is
not surprising since formation of EB-diol has been shown
to reach a plateau at exposures greater than 62.5 ppm BD
for 20 days, using THB-Val and THB-guanine adducts as
biomarkers (Koc et al., 1999; Swenberg et al., 2001).
Direct comparisons of pyr-Val to DNA cross-link adduct
formation can be made since animals from the same exposures
have been studied. Tretyakova and colleagues determined the
presence of N7-guanine-N7-guanine [1,4-bis(guan-7-yl)-2,
3-butanediol (bisN7-Gua-BD-diol)] and N7-guanine-N1-adenine
[1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7-Gua-N1-Ade-
BD-diol)] in liver, lung, kidney, brain, and thymus of rats and
mice after 10-day inhalation exposures to 6.25, 62.5, and
625 ppm BD (Goggin et al., 2007, 2008, 2009). Based on
DNA-DNA cross-links, mice form ~10-fold more DEB than
rats. The formation of DNA-DNA cross-links was highest in
liver. Thus, both pyr-Val and DNA-DNA cross-links show that
mice form much more DEB than rats. There were some
differences, however, between the two biomarkers. The
formation of pyr-Val saturated in rats at 200 ppm BD and
higher, while the DNA-DNA cross-links saturated at 62.5 ppm
BD, similar to our previous data on THB-Gua (Koc et al.,
1999). Furthermore, pyr-Val did not show a gender difference,
while DNA-DNA cross-links were twice as high in liver of
female rats and mice compared to males.
In rats, there was a decrease in the amounts of pyr-Val after
20 days of BD exposure to 62.5 ppm compared to that
measured after 10 days of exposure. Female rats exposed to
6.25 ppm BD for 10 or 20 days had similar amounts of pyr-Val
(Table 1). In both cases, we expected greater amounts of pyr-
Val in rats exposed for 20 days. The reason for this unexpected
finding is not clear. It is possible that exposure of erythrocytes
to DEB cross-links proteins or otherwise damages the cell
surface, leading to increased scavenging by the spleen. Walker
et al. (1992) showed that rat erythrocytes had a shortened
lifespan following high exposures to ethylene oxide. This was
thought to be due to a decreased lifespan of the older
erythrocytes, reducing the molecular dose of ethylene oxide
globin adducts in the cells exposed for the longest period, plus
greater release of juvenile erythrocytes from the bone marrow.
The similarity of pyr-Val amounts measured in the 20-day
F344 rats exposed to 62.5 ppm BD and the 90-day 1000 ppm
BD exposures in Sprague-Dawley rats previously reported
(Boysen et al., 2004, 2007a) might be due to a combination of
increased erythrocyte scavenging, dilution by increased
hematopoiesis, and saturation of metabolism at high concen-
trations of BD. Unfortunately, the exposure regime of the
present study was not designed to investigate potential effects
of exposure duration on the formation of pyr-Val or the
lifespan of erythrocytes. It was expected that pyr-Val adducts
would be higher after 20 days of exposure due to the additional
exposure time. In contrast, the present data suggest that the
lifespan of highly exposed rat erythrocytes may be shorter than
63 days. No such effect was seen in mice. To our knowledge,
no data have been reported in the literature on the lifespan of
erythrocytes in BD-exposed mice or rats. Formation of HB-Val
and THB-Val increases linearly up to 3 weeks in ICR female
mice exposed to 500 and 1000 ppm BD (Lee et al., 2005).
In the current study of pyr-Val formation, the exposures
reported herein were designed to address potential gender
differences in BD metabolism. At exposures longer in duration
(90 days) and higher concentrations (1000 ppm BD), formation
of HB-Val, pyr-Val, and THB-Val were reported to be 1.6-, 3-,
and 2-fold higher in female than in male rats, respectively
(Boysen et al., 2004; Swenberg et al., 2000). In the present
study, there were no statistically significant gender differences
FIG. 2. Ion chromatograms of pyr-Val from a B6C3F1 mouse (A) and
a F344 rat (B) exposed to 1 ppm BD for 10 days. Shown are the ion transitions
of the doubly charged analyte (m/z 417.3–158.3, top) and internal standard
peptides (m/z 418.8–158.7, bottom).
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in formation of pyr-Val in rats or mice. Therefore, if there is a
gender difference in formation of DEB, it may be only important
at high concentrations (> 625 ppm), after prolonged (90 days)
exposures, or in certain strains (e.g., Sprague-Dawley rats).
In addition to reaching a plateau, the exposure-response in
rats also shows evidence for decreases in slopes for pyr-Val
formation similar to the ones observed in mice at exposures
above 6.25 ppm. The mechanism behind these complex
response curves is not fully understood. It may be the result
of overlapping enzyme activities. P450 2E1 and P450 2A6
are involved in BD metabolism to EB, with P450 2E1 being
the high-affinity low-capacity isozyme and the P450 2A6 the
low-affinity high-capacity isozyme (Krause and Elfarra,
1997). The subsequent conversion of EB to DEB is catalyzed
by P450 2E1 (Krause and Elfarra, 1997) and potentially also
by P450 3A4 (Seaton et al., 1995). In rat liver microsomes,
the formation of DEB showed a change in slope similar to
the response for pyr-Val, while the formation was linear in
mouse liver microsomes. In addition, epoxide hydrolase and
alcohol dehydrogenase compete for the BD metabolites and
influence the half-life of free DEB (Kemper et al., 1998).
Lastly, inhibition of P450 2E1 by controlled phosphorylation
(Oesch-Bartlomowicz et al., 1998) or by covalent binding of
reactive metabolites to the active site similar to tert-butyl
acetylenes has been proposed (Blobaum et al., 2002; Boysen
et al., 2007b). Such hypotheses are supported by the
observation that p-nitrophenol hydroxylation activity
(specific P450 2E1 substrate) is reduced in microsomes
isolated from BD-diol–treated mice (Kemper et al.,
1998). Future research on mechanisms responsible for the
FIG. 3. Exposure-response of pyr-Val in male (solid lines) and female (dashed lines) B6C3F1 mice and F344 rats. (A) Mice were exposed to BD for 10 days.
(B) Mice were exposed to BD for 20 days. (C) Rats were exposed to BD for 10 days. (D) Rats were exposed to BD for 20 days. Rodents were exposed to BD by
inhalation, and globin was obtained and analyzed for pyr-Val as described in the ‘‘Material and Methods’’ section. Inserts in (A) and (C) show exposure-responses
at exposures below 7.5 ppm BD.
FIG. 4. Efficiency of pyr-Val adduct formation (picomoles per gram of
globin per parts per million of BD) and Hprt mutation induction in splenic
T cells from female B6C3F1 mice following inhalation exposure to BD. Mice
were exposed to BD for 10 days (5 day/week and 6 h/day) and then groups of
control and BD-exposed animals were necropsied 2 h or 4 weeks after the
cessation of exposures for respective measurements of pyr-Val and Hprt mutant
frequency (MF). pyr-Val data are from Boysen et al. (2004) and current work;
Hprt MF data are from an earlier report (Meng et al., 2001; Walker and Meng,
2000b; Walker et al., 2009). Data for pyr-Val adducts at 20 ppm BD and Hprt
MFs at 6.25 ppm are currently not available.
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regulation of BD metabolism are needed to better understand
the species and dose dependence of BD mutagenesis and
carcinogenesis.
Earlier, metabolite-specific Hprt mutation studies in mice,
and comparisons between biomarkers of exposure and effect in
mice exposed to BD or its epoxy intermediates, suggested that
the mutagenicity of BD at relatively low exposure concen-
trations (3–62.5 ppm) could be attributed to DEB (Meng et al.,
2001; Walker and Meng, 2000b). For example, previous
comparisons between the efficiency of formation of several
hemoglobin/DNA adducts and the efficiency of Hprt mutant
T-cell induction showed poor correlations between EB-specific
adducts and Hprt mutant frequencies but positive correlations
between THB-guanine adducts (derived from DEB and EB-
diol) in lung and mutant frequencies in T cells of BD-exposed
mice (Meng et al., 2001). Figure 4 compares the efficiency of
pyr-Val formation with the efficiency of Hprt mutant T-cell
induction in female mice following exposures of 3–1250 ppm
BD for 10 days and shows the strongest correlation to date
between in vivo formation of an exposure marker for a specific
BD epoxide intermediate (pyr-Val) and mutagenic responses
following BD exposures. Additional analyses are needed to fill
gaps in the pyr-Val and Hprt mutant frequency data for mice,
rats, and humans, but these preliminary data suggest that
in vivo amounts of this DEB-specific hemoglobin adduct may
be a highly predictive biomarker for BD-induced mutations and
cancer risk.
In summary, the results presented clearly demonstrate the
complexity of BD metabolism, including formation of DEB in
mice and rats. Therefore, quantitative data on DEB formation
cannot be simply translated to human exposures without
obtaining accurate measures of the metabolic rate in humans.
This can now be accomplished with similar assays on human
globin. We have analyzed over 300 human samples for the
presence of pyr-Val (data not shown) and are currently
performing similar assays for HB-Val and THB-Val. At
exposures between 0.1 and 1.0 ppm, it appears that humans
form ~10% of the pyr-Val formed by rats, which in turn form
about 10% of the pyr-Val formed by mice. Thus, the mouse
produces ~100-fold more pyr-Val per parts per million BD
than humans. Fred et al. (2008) recently suggested conversion
of individual adduct values into EB equivalents to determine
the carcinogenic and mutagenic potency of the individual
epoxides. When all data on BD-derived hemoglobin adducts
in mice, rats, and humans are available, such conversion will
quantitatively demonstrate differences in mutagenic and
carcinogenic potency of BD and its epoxide metabolites. It
will also be possible to construct comparisons of the
exposure-response for biomarkers of exposure (hemoglobin
adducts) and biomarkers of effect (mutations), including the
determination of exposures that do not result in increases in
mutations over the normal background (Swenberg et al.,
2008). These data will be very helpful in science-based risk
assessment.
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